Coherus Oncology (CHRS) Share-based Compensation (2013 - 2026)

Coherus Oncology has disclosed Share-based Compensation across 14 years of filings, most recently posting $2.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.4 million, down 55.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.0 million (down 45.93% YoY), and the FY2025 annual result was $17.0 million, down 38.98% from the prior year.
• Share-based Compensation came in at $2.4 million for Q1 2026 at Coherus Oncology, down from $2.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.9 million in Q1 2022 to a low of $184000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $6.9 million (2024), against an average of $7.0 million.
• Across the five-year window, Share-based Compensation surged 5309.24% in 2023 and plunged 56.39% in 2025, its largest moves.
• Coherus Oncology's Share-based Compensation stood at $11.7 million in 2022, then declined by 7.91% to $10.8 million in 2023, then tumbled by 40.88% to $6.4 million in 2024, then slumped by 56.39% to $2.8 million in 2025, then declined by 14.33% to $2.4 million in 2026.
• The last three Share-based Compensation figures came in at $2.4 million (Q1 2026), $2.8 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.